Home

sage therapeutics news, Therapeutics plunges FDA decision on depression drug, Sage Therapeutics fires of staff after FDA rejected MDD bid Pharmaceutical Technology

Sage Therapeutics (@SageBiotech)
Sage Therapeutics Biogen Announce to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug the Second Half of 2022 with Rolling Submission Expected
Sage Therapeutics CEO on drugs addressing mental health
Therapeutics
FDA approval for zuranolone hope postpartum depression
Sage Therapeutics Plummet on Subpar Depression-Treatment Study Results - WSJ
While Sage Therapeutics sees a window for depression drug, market is - MedCity News
Biogen Gives Sage $1.5 Billion In Deal To Develop Depression And Tremor Treatments | The Healthcare Technology Report.
Therapeutics - Timberline Construction
Sage Therapeutics stock stock offering, miss | Seeking
Sage wins priority review for depression drug - MassDevice
Sage Therapeutics Biogen Announce to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug the Second Half of 2022 with Rolling Submission Expected
Sage to cut 188 jobs after setback | Reuters
Sage Therapeutics fires of staff after FDA rejected MDD bid Pharmaceutical Technology
Maintains Sage Therapeutics (SAGE) Neutral Recommendation
Is Sage Therapeutics Stock Down 48% | InvestorPlace
Sage Therapeutics and Biogen pursue FDA approval zuranolone
Biogen-Sage Therapeutics depression pill priced at $15,900 | Reuters
Sage tumbles to record low on clinical depression pill setback Reuters
Sage Therapeutics' SAGE-718 granted Orphan Designation by European Medicines Agency for Huntington's Disease treatment - Pharma Journalist
Did SAGE Just CNS | BioSpace
Therapeutics plunges FDA decision on depression drug
Therapeutics Restructures To Support ZURZUVAE | Contract Pharma
Sage Therapeutics slumps, Biogen
Sage Therapeutics, Inc. Q4 - Results Earnings Call Presentation (NASDAQ:SAGE) | Seeking Alpha
Layoffs as Sage Therapeutics CNS pipeline
Biotech layoffs 2023: Sage Therapeutics cuts nearly half its in wake of FDA rejection - Boston Journal